ClinicalTrials.gg
RecruitingNCT05761015PERIPATEIUpdated Feb 27, 2026

Helping Osteoarthritis Patients to Walk With NSAID

A Phase 4 interventional study of therapeutic program including intermittent drug intake and multimodal rehabilitation program in Osteoarthritis, Knee, Osteoarthritis, Hip and Chronic Pain, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University Hospital, Clermont-Ferrand · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · University Hospital, Clermont-Ferrand.

Started
2023
the only one that year
Phase 4
Only one
of the 13
Registered
10th of 13
by date

Among the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand, this one is the only one that started in 2023, is the only one in phase 4, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

There is a lack of effective analgesic treatments to help walking patients with painful hip/knee osteoarthritis. Our team therefore imagined a new strategy lying on a multimodal rehabilitation walking program with the help of a transient intake of nonsteroidal anti-inflammatory drug (NSAID). NSAIDs are indeed known to act specifically on pain at movement, but their continuous intake would induce unacceptable side effects. To optimize the benefit/risk balance, the molecule to be chosen must fit to the patient's profile, and its intake should cover only the period of interest, i.e. planned walks. Our multimodal rehabilitation program will also include physical techniques such as appropriate footwear, a patient's education aiming at reducing fear/avoidance and spotting side effects of NSAIDs, and a prescription frame to avoid any overdosing.

This clinical study is a single-center, non-randomized, open label, one-arm trial, using drugs prescribed according to their label (i.e. osteoarthritis pain), pending a reinforced monitoring of side effects.

The primary endpoint is to evaluate efficacy and tolerance of a tailored and transient administration of NSAID within a rehabilitation walking program in patients with painful hip/knee osteoarthritis.

Secondary endpoints are to evaluate the adherence to the program and the factors influencing adherence; to identify the less well tolerated conditions of treatment (one condition being one molecule for one patient profile); to identify the factors of success among a set of baseline demographic, morphometric and psychometric variables; and to study the role of central sensitization (assessed by temporal summation) on the efficacy of treatment.

Read the detailed description

Study schedule:

  • Inclusion visit (V0): check of the eligibility criteria, explanation of the protocol, plan for a podiatric consultation, baseline questionnaires, and delivery of diary to collect efficacy outcomes.
  • Observation time (4 weeks): baseline measurement of efficacy outcomes (physical activity and pain at walk), podiatric consultation and improvement of footwear (including orthosis or soles).
  • Pre-intervention visit (V1) : collection of self-reported outcomes, measurement of temporal summation, 6-min walk test before and after NSAID test *, plan for the first 6-week intervention period and delivery of diary to collect efficacy and tolerance outcomes.
  • Intermediate within-intervention visit (after 6 weeks): collection of self-reported outcomes, blood sampling (biological tolerance outcomes), plan for the second 6-week intervention period and delivery of diary to collect efficacy and tolerance outcomes.
  • End-of-study visit: collection of self-reported outcomes, blood sampling (biological tolerance outcomes), and collection of last efficacy outcomes (anxiety, depression, kinesiophobia, global impression of change).

    • The patient will undergo two 6-min walk tests at the pre-intervention visit, one before and one 45 min. after oral administration of the NSAID. The patient will be considered as responsive to the NSAID if one of the following criteria occurs: a 15% increase (or more) of the time-to-first pain at walk, self-defined as bothering; a 1-point decrease (or more) of pain intensity (out of 10) throughout the test; or a 15% increase (or more) of the walked distance, if this was \< 200 m at the first test. Only patients responsive to the NSAID will continue the trial.

The sequence of successes will be treated in Bayesian analyses. Sequential analyses with be conducted stepwise. At each step, the decision to stop or to keep going will be taken, until a maximum of 50 cases eligible for analysis.

  • 1st step (N=20): stop for efficacy if more than 11 successes; stop for non-efficacy if less than 6 successes; continuation otherwise (20 supplementary patients);
  • 2nd step (N=40): stop for efficacy if more than 17 successes; stop for non-efficacy if less than 16 successes; continuation otherwise (20 supplementary patients);
  • 3rd step (N=50): efficacy if more than 21 successes; non-efficacy otherwise
03

Conditions studied

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
  • Chronic Pain

Keywords

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
  • pain at movement
  • nonsteroidal anti-inflammatory drug
  • acetaminophen
  • paracetamol
  • personalized medicine
  • pharmacovigilance
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Uni- or bilateral hip or knee idiopathic osteoarthrosis (ACR criteria, Kellgren-Lawrence grade 2 or more on recent X-ray), responsible for pain since 3 at least months, and pain at walking which intensity is at least 4/10 on a numerical rating scale.
  • Less than 3 relevant walks (at least 20 minutes or 1000 km) a week.
  • Ability to understand and to follow the protocol, and to answer the questionnaires

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Legal protection
  • Body weight \< 40 kg or underweight
  • Body weight >120 kg or obesity
  • Unability to walk, or unability to walk without support devices (sticks, crutches, orthoses and knee pads are allowed)
  • Secondary osteoarthrosis (rheumatism, septic arthritis, recent osteonecrosis, hemochromatosis, gout, acromegalia…).
  • Concomitant general bone disease (Paget, Reiter…).
  • Concomitant and relevant painful disease else than due to osteoarthrosis (e.g. neuropathic pain, fibromyalgia…)
  • Previous recent intervention (e.g. surgery, arthroscopy, joint infiltration) expected to relief osteoarthrosis pain throughout the study period.
  • Planned intervention similar to those abovementioned, during the study period.
  • Recent initiation of any new analgesic treatment (including systemic ).
  • Planned initiation of any program expected to relief osteoarthrosis pain during the study period, such as physiotherapy, cognitive behavioral therapy…).
  • Planned major surgery during the study period.
  • Current cancer disease.
  • .
  • disease.
  • Concomitant topical or systemic NSAID treatment.
  • Chronic strong opioid intake.
  • Concomitant insulin therapy.
  • Any absolute or relevant to NSAIDs or acetaminophen, according to the French drug agency
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Intervention

    there is only one intervention arm and no control arm; the Bayesian analysis will be conducted under hypothetical estimates of superiority vs. control.

    Drug: therapeutic program including intermittent drug intake and multimodal rehabilitation program

Interventions

  • Drugtherapeutic program including intermittent drug intake and multimodal rehabilitation program

    The prescribed NSAID molecule shall be chosen according to the patient's risk profile: * gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ; * cardiovascular risk (according to Agostino scale \& SCORE); The molecule with therefore be: * no risk: niflumic acid, 250 mg per intake; * gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole; * cardiovascular risk only: ketoprofen, 50-100 mg per intake; * double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so. One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week.

06

What researchers measure

Primary outcomes

  1. Success

    success of the therapeutic program (defined by a 30%-increase (or more) of the monthly number of target moves from the baseline observation values, with no treatment discontinuation for NSAID side effects)

    Time frame: V1 (pre-intervention visit) + 12 weeks

Secondary outcomes

  1. Self-declared physical activity (efficacy outcome)

    Global Physical Activity Questionnaire (GPAQ)

    Time frame: V1 (pre-intervention visit)

  2. Self-declared physical activity (efficacy outcome)

    Global Physical Activity Questionnaire (GPAQ)

    Time frame: V1 (pre-intervention visit) + 6 weeks

  3. Self-declared physical activity (efficacy outcome)

    Global Physical Activity Questionnaire (GPAQ)

    Time frame: V1 (pre-intervention visit) + 12 weeks

  4. Actual physical activity (efficacy outcome)

    Number of steps per day assessed by pedometer

    Time frame: V1 (pre-intervention visit)

  5. Actual physical activity (efficacy outcome)

    Number of steps per day assessed by pedometer

    Time frame: V1 (pre-intervention visit)+ 6 weeks

  6. Actual physical activity (efficacy outcome)

    Number of steps per day assessed by pedometer

    Time frame: V1 (pre-intervention visit) + 12 weeks

  7. Pain at walk during the two last weeks (efficacy outcome)

    Visual Analogic Scale VAS (11-point numerical rating scale (from 0 = "no pain" to 10) "the worst pain imaginable")

    Time frame: V1 (pre-intervention visit)

  8. Pain at walk during the two last weeks (efficacy outcome)

    Visual Analogic Scale VAS (11-point numerical rating scale (from 0 = "no pain" to 10) "the worst pain imaginable")

    Time frame: V1 (pre-intervention visit) + 6 weeks

  9. Pain at walk during the two last weeks (efficacy outcome)

    Visual Analogic Scale VAS (11-point numerical rating scale (from 0 = "no pain" to 10) "the worst pain imaginable")

    Time frame: V1 (pre-intervention visit)+ 12 weeks

  10. Patient's Global Impression of Change (efficacy outcome)

    7-item scale

    Time frame: V1 (pre-intervention visit) + 12 weeks

  11. kinesiophobia (efficacy outcome)

    Tampa Scale of Kinesiophobia (TSK)

    Time frame: V1 (pre-intervention visit) + 12 weeks

  12. level of anxious state (efficacy outcome)

    Hospital Anxiety and Depression scale (HADS)

    Time frame: V1 (pre-intervention visit) + 12 weeks

  13. level of depressive state (efficacy outcome)

    Hospital Anxiety and Depression scale (HADS)

    Time frame: V1 (pre-intervention visit)+ 12 weeks

Other outcomes

  1. impairment of renal function (tolerance outcome)

    either a 15%-increase (or more) of creatininemia from baseline, or a glomerular filtration rate \<60 mL.min-1 (MDRD), or creatininemia exceeding 1.5-times the upper limit of the lab's normative values

    Time frame: V0 (inclusion)

  2. impairment of renal function (tolerance outcome)

    either a 15%-increase (or more) of creatininemia from baseline, or a glomerular filtration rate \<60 mL.min-1 (MDRD), or creatininemia exceeding 1.5-times the upper limit of the lab's normative values

    Time frame: V1 (pre-intervention visit) + 6 weeks

  3. impairment of renal function (tolerance outcome)

    either a 15%-increase (or more) of creatininemia from baseline, or a glomerular filtration rate \<60 mL.min-1 (MDRD), or creatininemia exceeding 1.5-times the upper limit of the lab's normative values

    Time frame: V1 (pre-intervention visit)+ 12 weeks

  4. impairment of liver function (tolerance outcome)

    blood transaminase levels exceeding 2.5-times the upper limit of the lab's normative values, or the occurrence of any relevant abnormality on the liver blood parameters

    Time frame: V0 (inclusion)

  5. impairment of liver function (tolerance outcome)

    blood transaminase levels exceeding 2.5-times the upper limit of the lab's normative values, or the occurrence of any relevant abnormality on the liver blood parameters

    Time frame: V1 (pre-intervention visit) + 6 weeks

  6. impairment of liver function (tolerance outcome)

    blood transaminase levels exceeding 2.5-times the upper limit of the lab's normative values, or the occurrence of any relevant abnormality on the liver blood parameters

    Time frame: V1 (pre-intervention visit) + 12 weeks

  7. search for anemia (tolerance outcome)

    15%-decrease (or more) of hemoglobinemia from baseline

    Time frame: V0 (inclusion)

  8. search for anemia (tolerance outcome)

    15%-decrease (or more) of hemoglobinemia from baseline

    Time frame: V1 (pre-intervention visit) + 6 weeks

  9. search for anemia (tolerance outcome)

    15%-decrease (or more) of hemoglobinemia from baseline

    Time frame: V1 (pre-intervention visit) + 12 weeks

  10. relevant digestive event (tolerance outcome)

    persistent gastralgia despite proton-pump inhibitor treatment, or any symptom of hematemesis or rectal bleeding

    Time frame: V1 (pre-intervention visit) + 6 weeks

  11. relevant digestive event (tolerance outcome)

    persistent gastralgia despite proton-pump inhibitor treatment, or any symptom of hematemesis or rectal bleeding

    Time frame: V1 (pre-intervention visit) + 12 weeks

  12. bleeding event (tolerance outcome)

    any abnormal bleeding event if the prescribed NSAID (Non-steroidal anti-inflammatory drugs) is COX (Cyclo-OXygenase inhibitors)-1 selective

    Time frame: V1 (pre-intervention visit) + 6 weeks

  13. bleeding event (tolerance outcome)

    any abnormal bleeding event if the prescribed NSAID (Non-steroidal anti-inflammatory drugs) is COX (Cyclo-OXygenase inhibitors)-1 selective

    Time frame: V1 (pre-intervention visit) + 12 weeks

  14. thrombotic event (tolerance outcome)

    any thrombotic event if the prescribed NSAID is COX-2 selective

    Time frame: V1 (pre-intervention visit) + 6 weeks

  15. thrombotic event (tolerance outcome)

    any thrombotic event if the prescribed NSAID is COX-2 selective

    Time frame: V1 (pre-intervention visit) + 12 weeks

  16. serious adverse event (SAE) (tolerance outcome)

    any SAE considered as relevant by the principal investigator, and possibly due to the intervention

    Time frame: V1 (pre-intervention visit) + 6 weeks

  17. serious adverse event (SAE) (tolerance outcome)

    any SAE considered as relevant by the principal investigator, and possibly due to the intervention

    Time frame: V1 (pre-intervention visit) + 12 weeks

  18. EPICES scale (Evaluation of Precariousness and Health Inequalities in Health Examination Centers) (tolerance outcome)

    social precarity

    Time frame: V0 (inclusion)

  19. Pain Catastrophizing Scale (PCS) (tolerance outcome)

    pain catastrophizing

    Time frame: V0 (inclusion)

  20. Tampa Scale of Kinesiophobia (TSK) (tolerance outcome)

    kinesiophobia

    Time frame: V0 (inclusion)

  21. level of anxious state (tolerance outcome)

    Hospital Anxiety and Depression scale (HADS)

    Time frame: V0 (inclusion)

  22. level of depressive state (tolerance outcome)

    Hospital Anxiety and Depression scale (HADS)

    Time frame: V0 (inclusion)

  23. temporal summation of pain (tolerance outcome)

    measurement both at the forearm ipsilateral to the most painful joint and at the skin area referred to the most painful joint; temporal summation is measured by repeated stimuli with a von Frey filament (180g).

    Time frame: V0 (inclusion ) + 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2028, 52 months after the start.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 52 months is above that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 9, 2023
StartActual
Dec 14, 2023
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05761015
Collaborators
Fondation Apicil, SARL BOUCHARENC, Saint-Chély d'Apcher, France, Université d'Auvergne, NEURO-DOL (UMR 1107 INSERM / UCA)
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Dec 14, 2023
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
04 73 75 11 95

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion